Summary: | Migraine is a chronic and disabling disorder affecting >1 billion individuals worldwide.
Current treatments for the prevention of migraine include antihypertensives, antiepileptics, and antidepressants, and all share limited tolerability and adherence, highlighting the need for the development of new disease-specific and mechanism-based agents. In this context, four novel anti-calcitonin gene-related peptide monoclonal antibodies have been investigated in a large Phase II–III clinical programme and showed similar efficacy to the currently used drugs for migraine prevention but with a significantly improved safety profile, as highlighted in this review. It is expected that patient compliance with treatment will increase with the use of these therapies, improving the long-term overall outcome of migraine. However, real-world evidence is needed to confirm the tolerability and safety of anti-calcitonin gene-related peptide monoclonal antibodies before the drugs can be established as first-line agents in the prophylactic treatment of migraine.
|